Pharma & Healthcare
Global Monoclonal Antibodies for Plaque Psoriasis Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 04, 25
- ID: 537637
- Pages: 167
- Figures: 158
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Monoclonal Antibodies for Plaque Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Janssen Biotech, Inc.
Biocon Ltd.
Novartis AG
Eli Lilly & Co.
Bausch Health Cos., Inc
Sun Pharmaceutical Industries Ltd.
Almirall SA
AbbVie, Inc.
UCB, Inc.
Chongqing Genrix Biopharmaceutical Co., Ltd
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
5-100 mg/mL
100-200 mg/mL
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Monoclonal Antibodies for Plaque Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Monoclonal Antibodies for Plaque Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Janssen Biotech, Inc.
Biocon Ltd.
Novartis AG
Eli Lilly & Co.
Bausch Health Cos., Inc
Sun Pharmaceutical Industries Ltd.
Almirall SA
AbbVie, Inc.
UCB, Inc.
Chongqing Genrix Biopharmaceutical Co., Ltd
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
5-100 mg/mL
100-200 mg/mL
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Monoclonal Antibodies for Plaque Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Monoclonal Antibodies for Plaque Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 5-100 mg/mL
1.2.3 100-200 mg/mL
1.3 Market Segmentation by Application
1.3.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Monoclonal Antibodies for Plaque Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Monoclonal Antibodies for Plaque Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 5-100 mg/mL Market Size by Manufacturers
3.5.2 100-200 mg/mL Market Size by Manufacturers
3.6 Global Monoclonal Antibodies for Plaque Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Corporation Information
11.1.2 Janssen Biotech, Inc. Business Overview
11.1.3 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.1.4 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.1.6 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.1.7 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.1.8 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.1.9 Janssen Biotech, Inc. Recent Developments
11.2 Biocon Ltd.
11.2.1 Biocon Ltd. Corporation Information
11.2.2 Biocon Ltd. Business Overview
11.2.3 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.2.4 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.2.6 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.2.7 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.2.8 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.2.9 Biocon Ltd. Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.3.4 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.3.6 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.3.7 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.3.8 Novartis AG Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.3.9 Novartis AG Recent Developments
11.4 Eli Lilly & Co.
11.4.1 Eli Lilly & Co. Corporation Information
11.4.2 Eli Lilly & Co. Business Overview
11.4.3 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.4.4 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.4.6 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.4.7 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.4.8 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.4.9 Eli Lilly & Co. Recent Developments
11.5 Bausch Health Cos., Inc
11.5.1 Bausch Health Cos., Inc Corporation Information
11.5.2 Bausch Health Cos., Inc Business Overview
11.5.3 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.5.4 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.5.6 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.5.7 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.5.8 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.5.9 Bausch Health Cos., Inc Recent Developments
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.6.4 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.7 Almirall SA
11.7.1 Almirall SA Corporation Information
11.7.2 Almirall SA Business Overview
11.7.3 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.7.4 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Almirall SA Recent Developments
11.8 AbbVie, Inc.
11.8.1 AbbVie, Inc. Corporation Information
11.8.2 AbbVie, Inc. Business Overview
11.8.3 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.8.4 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 AbbVie, Inc. Recent Developments
11.9 UCB, Inc.
11.9.1 UCB, Inc. Corporation Information
11.9.2 UCB, Inc. Business Overview
11.9.3 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.9.4 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 UCB, Inc. Recent Developments
11.10 Chongqing Genrix Biopharmaceutical Co., Ltd
11.10.1 Chongqing Genrix Biopharmaceutical Co., Ltd Corporation Information
11.10.2 Chongqing Genrix Biopharmaceutical Co., Ltd Business Overview
11.10.3 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.10.4 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
11.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd
11.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Corporation Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Business Overview
11.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Monoclonal Antibodies for Plaque Psoriasis Industry Chain
12.2 Monoclonal Antibodies for Plaque Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Monoclonal Antibodies for Plaque Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Monoclonal Antibodies for Plaque Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Monoclonal Antibodies for Plaque Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Monoclonal Antibodies for Plaque Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Monoclonal Antibodies for Plaque Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 5-100 mg/mL
1.2.3 100-200 mg/mL
1.3 Market Segmentation by Application
1.3.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Monoclonal Antibodies for Plaque Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Monoclonal Antibodies for Plaque Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 5-100 mg/mL Market Size by Manufacturers
3.5.2 100-200 mg/mL Market Size by Manufacturers
3.6 Global Monoclonal Antibodies for Plaque Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Corporation Information
11.1.2 Janssen Biotech, Inc. Business Overview
11.1.3 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.1.4 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.1.6 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.1.7 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.1.8 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.1.9 Janssen Biotech, Inc. Recent Developments
11.2 Biocon Ltd.
11.2.1 Biocon Ltd. Corporation Information
11.2.2 Biocon Ltd. Business Overview
11.2.3 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.2.4 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.2.6 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.2.7 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.2.8 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.2.9 Biocon Ltd. Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.3.4 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.3.6 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.3.7 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.3.8 Novartis AG Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.3.9 Novartis AG Recent Developments
11.4 Eli Lilly & Co.
11.4.1 Eli Lilly & Co. Corporation Information
11.4.2 Eli Lilly & Co. Business Overview
11.4.3 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.4.4 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.4.6 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.4.7 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.4.8 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.4.9 Eli Lilly & Co. Recent Developments
11.5 Bausch Health Cos., Inc
11.5.1 Bausch Health Cos., Inc Corporation Information
11.5.2 Bausch Health Cos., Inc Business Overview
11.5.3 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.5.4 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Product in 2024
11.5.6 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Application in 2024
11.5.7 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales by Geographic Area in 2024
11.5.8 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
11.5.9 Bausch Health Cos., Inc Recent Developments
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.6.4 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.7 Almirall SA
11.7.1 Almirall SA Corporation Information
11.7.2 Almirall SA Business Overview
11.7.3 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.7.4 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Almirall SA Recent Developments
11.8 AbbVie, Inc.
11.8.1 AbbVie, Inc. Corporation Information
11.8.2 AbbVie, Inc. Business Overview
11.8.3 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.8.4 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 AbbVie, Inc. Recent Developments
11.9 UCB, Inc.
11.9.1 UCB, Inc. Corporation Information
11.9.2 UCB, Inc. Business Overview
11.9.3 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.9.4 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 UCB, Inc. Recent Developments
11.10 Chongqing Genrix Biopharmaceutical Co., Ltd
11.10.1 Chongqing Genrix Biopharmaceutical Co., Ltd Corporation Information
11.10.2 Chongqing Genrix Biopharmaceutical Co., Ltd Business Overview
11.10.3 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.10.4 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
11.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd
11.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Corporation Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Business Overview
11.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Models, Descriptions and Specifications
11.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Monoclonal Antibodies for Plaque Psoriasis Industry Chain
12.2 Monoclonal Antibodies for Plaque Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Monoclonal Antibodies for Plaque Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Monoclonal Antibodies for Plaque Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Monoclonal Antibodies for Plaque Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Monoclonal Antibodies for Plaque Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Monoclonal Antibodies for Plaque Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Monoclonal Antibodies for Plaque Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Monoclonal Antibodies for Plaque Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Plaque Psoriasis as of 2024)
Table 16. Global Monoclonal Antibodies for Plaque Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Monoclonal Antibodies for Plaque Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Monoclonal Antibodies for Plaque Psoriasis Manufacturing Base and Headquarters
Table 19. Global Monoclonal Antibodies for Plaque Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Monoclonal Antibodies for Plaque Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. Monoclonal Antibodies for Plaque Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Monoclonal Antibodies for Plaque Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 37. North America Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Monoclonal Antibodies for Plaque Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Janssen Biotech, Inc. Corporation Information
Table 51. Janssen Biotech, Inc. Description and Major Businesses
Table 52. Janssen Biotech, Inc. Product Models, Descriptions and Specifications
Table 53. Janssen Biotech, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Janssen Biotech, Inc. Sales Value Proportion by Product in 2024
Table 55. Janssen Biotech, Inc. Sales Value Proportion by Application in 2024
Table 56. Janssen Biotech, Inc. Sales Value Proportion by Geographic Area in 2024
Table 57. Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 58. Janssen Biotech, Inc. Recent Developments
Table 59. Biocon Ltd. Corporation Information
Table 60. Biocon Ltd. Description and Major Businesses
Table 61. Biocon Ltd. Product Models, Descriptions and Specifications
Table 62. Biocon Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Biocon Ltd. Sales Value Proportion by Product in 2024
Table 64. Biocon Ltd. Sales Value Proportion by Application in 2024
Table 65. Biocon Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 67. Biocon Ltd. Recent Developments
Table 68. Novartis AG Corporation Information
Table 69. Novartis AG Description and Major Businesses
Table 70. Novartis AG Product Models, Descriptions and Specifications
Table 71. Novartis AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis AG Sales Value Proportion by Product in 2024
Table 73. Novartis AG Sales Value Proportion by Application in 2024
Table 74. Novartis AG Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis AG Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 76. Novartis AG Recent Developments
Table 77. Eli Lilly & Co. Corporation Information
Table 78. Eli Lilly & Co. Description and Major Businesses
Table 79. Eli Lilly & Co. Product Models, Descriptions and Specifications
Table 80. Eli Lilly & Co. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Eli Lilly & Co. Sales Value Proportion by Product in 2024
Table 82. Eli Lilly & Co. Sales Value Proportion by Application in 2024
Table 83. Eli Lilly & Co. Sales Value Proportion by Geographic Area in 2024
Table 84. Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 85. Eli Lilly & Co. Recent Developments
Table 86. Bausch Health Cos., Inc Corporation Information
Table 87. Bausch Health Cos., Inc Description and Major Businesses
Table 88. Bausch Health Cos., Inc Product Models, Descriptions and Specifications
Table 89. Bausch Health Cos., Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Bausch Health Cos., Inc Sales Value Proportion by Product in 2024
Table 91. Bausch Health Cos., Inc Sales Value Proportion by Application in 2024
Table 92. Bausch Health Cos., Inc Sales Value Proportion by Geographic Area in 2024
Table 93. Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 94. Bausch Health Cos., Inc Recent Developments
Table 95. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 96. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 97. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 98. Sun Pharmaceutical Industries Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 100. Almirall SA Corporation Information
Table 101. Almirall SA Description and Major Businesses
Table 102. Almirall SA Product Models, Descriptions and Specifications
Table 103. Almirall SA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Almirall SA Recent Developments
Table 105. AbbVie, Inc. Corporation Information
Table 106. AbbVie, Inc. Description and Major Businesses
Table 107. AbbVie, Inc. Product Models, Descriptions and Specifications
Table 108. AbbVie, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. AbbVie, Inc. Recent Developments
Table 110. UCB, Inc. Corporation Information
Table 111. UCB, Inc. Description and Major Businesses
Table 112. UCB, Inc. Product Models, Descriptions and Specifications
Table 113. UCB, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. UCB, Inc. Recent Developments
Table 115. Chongqing Genrix Biopharmaceutical Co., Ltd Corporation Information
Table 116. Chongqing Genrix Biopharmaceutical Co., Ltd Description and Major Businesses
Table 117. Chongqing Genrix Biopharmaceutical Co., Ltd Product Models, Descriptions and Specifications
Table 118. Chongqing Genrix Biopharmaceutical Co., Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
Table 120. Jiangsu Hengrui Pharmaceuticals Co., Ltd Corporation Information
Table 121. Jiangsu Hengrui Pharmaceuticals Co., Ltd Description and Major Businesses
Table 122. Jiangsu Hengrui Pharmaceuticals Co., Ltd Product Models, Descriptions and Specifications
Table 123. Jiangsu Hengrui Pharmaceuticals Co., Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Monoclonal Antibodies for Plaque Psoriasis Product Picture
Figure 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 5-100 mg/mL Product Picture
Figure 4. 100-200 mg/mL Product Picture
Figure 5. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Others
Figure 9. Monoclonal Antibodies for Plaque Psoriasis Report Years Considered
Figure 10. Global Monoclonal Antibodies for Plaque Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 12. Global Monoclonal Antibodies for Plaque Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region (2020-2031)
Figure 14. Global Monoclonal Antibodies for Plaque Psoriasis Sales (2020-2031) & (K Units)
Figure 15. Global Monoclonal Antibodies for Plaque Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Volume Market Share in 2024
Figure 18. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. 5-100 mg/mL Revenue Market Share by Manufacturer in 2024
Figure 21. 100-200 mg/mL Revenue Market Share by Manufacturer in 2024
Figure 22. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2020-2031)
Figure 23. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2020-2031)
Figure 24. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2020-2031)
Figure 25. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2020-2031)
Figure 26. North America Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 27. North America Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 29. North America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 39. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 44. France Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 59. India Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 80. Monoclonal Antibodies for Plaque Psoriasis Industry Chain Mapping
Figure 81. Regional Monoclonal Antibodies for Plaque Psoriasis Manufacturing Base Distribution (%)
Figure 82. Global Monoclonal Antibodies for Plaque Psoriasis Production Market Share by Region (2020-2031)
Figure 83. Monoclonal Antibodies for Plaque Psoriasis Production Process
Figure 84. Regional Monoclonal Antibodies for Plaque Psoriasis Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Table 1. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Monoclonal Antibodies for Plaque Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Monoclonal Antibodies for Plaque Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Monoclonal Antibodies for Plaque Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Plaque Psoriasis as of 2024)
Table 16. Global Monoclonal Antibodies for Plaque Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Monoclonal Antibodies for Plaque Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Monoclonal Antibodies for Plaque Psoriasis Manufacturing Base and Headquarters
Table 19. Global Monoclonal Antibodies for Plaque Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Monoclonal Antibodies for Plaque Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. Monoclonal Antibodies for Plaque Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Monoclonal Antibodies for Plaque Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 37. North America Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Monoclonal Antibodies for Plaque Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Janssen Biotech, Inc. Corporation Information
Table 51. Janssen Biotech, Inc. Description and Major Businesses
Table 52. Janssen Biotech, Inc. Product Models, Descriptions and Specifications
Table 53. Janssen Biotech, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Janssen Biotech, Inc. Sales Value Proportion by Product in 2024
Table 55. Janssen Biotech, Inc. Sales Value Proportion by Application in 2024
Table 56. Janssen Biotech, Inc. Sales Value Proportion by Geographic Area in 2024
Table 57. Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 58. Janssen Biotech, Inc. Recent Developments
Table 59. Biocon Ltd. Corporation Information
Table 60. Biocon Ltd. Description and Major Businesses
Table 61. Biocon Ltd. Product Models, Descriptions and Specifications
Table 62. Biocon Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Biocon Ltd. Sales Value Proportion by Product in 2024
Table 64. Biocon Ltd. Sales Value Proportion by Application in 2024
Table 65. Biocon Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 67. Biocon Ltd. Recent Developments
Table 68. Novartis AG Corporation Information
Table 69. Novartis AG Description and Major Businesses
Table 70. Novartis AG Product Models, Descriptions and Specifications
Table 71. Novartis AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis AG Sales Value Proportion by Product in 2024
Table 73. Novartis AG Sales Value Proportion by Application in 2024
Table 74. Novartis AG Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis AG Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 76. Novartis AG Recent Developments
Table 77. Eli Lilly & Co. Corporation Information
Table 78. Eli Lilly & Co. Description and Major Businesses
Table 79. Eli Lilly & Co. Product Models, Descriptions and Specifications
Table 80. Eli Lilly & Co. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Eli Lilly & Co. Sales Value Proportion by Product in 2024
Table 82. Eli Lilly & Co. Sales Value Proportion by Application in 2024
Table 83. Eli Lilly & Co. Sales Value Proportion by Geographic Area in 2024
Table 84. Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 85. Eli Lilly & Co. Recent Developments
Table 86. Bausch Health Cos., Inc Corporation Information
Table 87. Bausch Health Cos., Inc Description and Major Businesses
Table 88. Bausch Health Cos., Inc Product Models, Descriptions and Specifications
Table 89. Bausch Health Cos., Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Bausch Health Cos., Inc Sales Value Proportion by Product in 2024
Table 91. Bausch Health Cos., Inc Sales Value Proportion by Application in 2024
Table 92. Bausch Health Cos., Inc Sales Value Proportion by Geographic Area in 2024
Table 93. Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis SWOT Analysis
Table 94. Bausch Health Cos., Inc Recent Developments
Table 95. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 96. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 97. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 98. Sun Pharmaceutical Industries Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 100. Almirall SA Corporation Information
Table 101. Almirall SA Description and Major Businesses
Table 102. Almirall SA Product Models, Descriptions and Specifications
Table 103. Almirall SA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Almirall SA Recent Developments
Table 105. AbbVie, Inc. Corporation Information
Table 106. AbbVie, Inc. Description and Major Businesses
Table 107. AbbVie, Inc. Product Models, Descriptions and Specifications
Table 108. AbbVie, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. AbbVie, Inc. Recent Developments
Table 110. UCB, Inc. Corporation Information
Table 111. UCB, Inc. Description and Major Businesses
Table 112. UCB, Inc. Product Models, Descriptions and Specifications
Table 113. UCB, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. UCB, Inc. Recent Developments
Table 115. Chongqing Genrix Biopharmaceutical Co., Ltd Corporation Information
Table 116. Chongqing Genrix Biopharmaceutical Co., Ltd Description and Major Businesses
Table 117. Chongqing Genrix Biopharmaceutical Co., Ltd Product Models, Descriptions and Specifications
Table 118. Chongqing Genrix Biopharmaceutical Co., Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
Table 120. Jiangsu Hengrui Pharmaceuticals Co., Ltd Corporation Information
Table 121. Jiangsu Hengrui Pharmaceuticals Co., Ltd Description and Major Businesses
Table 122. Jiangsu Hengrui Pharmaceuticals Co., Ltd Product Models, Descriptions and Specifications
Table 123. Jiangsu Hengrui Pharmaceuticals Co., Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Monoclonal Antibodies for Plaque Psoriasis Product Picture
Figure 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 5-100 mg/mL Product Picture
Figure 4. 100-200 mg/mL Product Picture
Figure 5. Global Monoclonal Antibodies for Plaque Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Others
Figure 9. Monoclonal Antibodies for Plaque Psoriasis Report Years Considered
Figure 10. Global Monoclonal Antibodies for Plaque Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 12. Global Monoclonal Antibodies for Plaque Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region (2020-2031)
Figure 14. Global Monoclonal Antibodies for Plaque Psoriasis Sales (2020-2031) & (K Units)
Figure 15. Global Monoclonal Antibodies for Plaque Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Volume Market Share in 2024
Figure 18. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. 5-100 mg/mL Revenue Market Share by Manufacturer in 2024
Figure 21. 100-200 mg/mL Revenue Market Share by Manufacturer in 2024
Figure 22. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2020-2031)
Figure 23. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2020-2031)
Figure 24. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2020-2031)
Figure 25. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2020-2031)
Figure 26. North America Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 27. North America Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 29. North America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 39. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 44. France Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 59. India Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Monoclonal Antibodies for Plaque Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Monoclonal Antibodies for Plaque Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 80. Monoclonal Antibodies for Plaque Psoriasis Industry Chain Mapping
Figure 81. Regional Monoclonal Antibodies for Plaque Psoriasis Manufacturing Base Distribution (%)
Figure 82. Global Monoclonal Antibodies for Plaque Psoriasis Production Market Share by Region (2020-2031)
Figure 83. Monoclonal Antibodies for Plaque Psoriasis Production Process
Figure 84. Regional Monoclonal Antibodies for Plaque Psoriasis Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232